InfuSystem Hlds

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Integrated Therapy Services and Durable Medical Equipment segments. The Integrated Therapy Services segment focuses on providing electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics, and hospital outpatient oncology clinics. The Durable Medical Equipment segment is involved in the rental, sale or leasing of pole-mounted and ambulatory infusion pumps to oncology practices, hospitals, and other clinical settings. The company was founded in August 2005 and headquartered in Rochester Hills, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InfuSystem reports revenue growth but faces supply chain challenges

InfuSystem's Q4 2022 performance showed revenue growth but a decrease in adjusted EBITDA, with a focus on strategic partnerships and conservative guidance for 2023.
The company faces challenges with supply chain issues, reporting delays, and internal control deficiencies, but is actively addressing these issues.
Opportunities lie in expanding the supplier base, enhancing product offerings, and expecting gradual revenue growth in 2023, supported by key partnerships and growth initiatives.

InfuSystem reports record Q1 revenue, expands partnerships for growth

InfuSystem's Q1 2023 performance reflects strong revenue growth, successful partnerships, and strategic expansions, positioning the company for continued success in the healthcare services sector.
While facing challenges such as higher expenses and reimbursement complexities, InfuSystem's focus on innovation and financial stability underscores its resilience and growth potential.
By reaffirming annual guidance and emphasizing sustainable growth strategies, InfuSystem demonstrates a clear vision for driving profitability and market leadership in the coming quarters.

InfuSystem reports robust Q2 earnings, eyes growth in Wound Care

InfuSystem Holdings, Inc. delivered a strong performance in Q2 2023, driven by revenue growth and strategic business decisions. The company's financial results, progress in addressing internal control deficiencies, and raised guidance indicate a positive outlook for future growth. While challenges exist in scaling certain business segments, InfuSystem is well-positioned to capitalize on opportunities in Wound Care and the Sanara joint venture.

InfuSystem reports record Q3 revenue growth and strategic expansion plans

InfuSystem's Q3 2023 performance reflects robust revenue growth, improved profitability, and strategic initiatives for future expansion and operational efficiency.
While facing challenges such as margin pressures and market competition, the company's strengths in oncology and operational enhancements position it for long-term success.
Opportunities in revenue diversification, service expansion, and market presence offer InfuSystem avenues for sustained growth and profitability.
Overall, InfuSystem's strong financial results, strategic focus on growth drivers, and optimism for future performance paint a positive outlook for investors and stakeholders.

InfuSystem Hlds (INFU) reports record revenue in Q4 2023

InfuSystem Hlds (INFU) delivered a robust performance in Q4 2023, showcasing revenue growth and margin improvement. With a strategic focus on core business expansion and operational excellence, the company aims for steady growth in 2024 amidst industry challenges and regulatory changes.

InfuSystem reports strong Q1 revenue growth and strategic partnerships

InfuSystem's Q1 performance reflects revenue growth and profitability improvements driven by operational enhancements.
The company's strategic partnerships and focus on high-potential opportunities position it for sustained growth.
Challenges include market focus shifts and balancing expenses with revenue growth for long-term success.
Overall, InfuSystem's performance outlook remains positive, with confidence in achieving revenue and EBITDA targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Patient Services and Device Solutions segments. The Patient Services segment involves the durable medical equipment, clinic-to-home health care, logistics and billing, and oncology business. The Device Solutions segment includes the sale or rent of new and pre-owned pole-mounted and ambulatory infusion pumps, treatment-related consumables, biomedical recertification, maintenance and repair services for oncology practices. The company was founded by Steven E. Watkins in August 2005 and headquartered in Rochester Hills, MI.

InfuSystem Holdings, Inc. (NYSE:INFU ) Q3 2024 Results Conference Call November 7, 2024 9:00 AM ET Company Participants Joe Dorame - Managing Partner Rich Dilorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Jim Sidoti - Sidoti & Company Brooks O'Neil - Lake Street Capital Markets Kyle Bauser - B. Riley Securities Matt Hewitt - Craig-Hallum Capital Group Aaron Warwick - Breakout Investors Operator Good day, and welcome to the InfuSystem Third Quarter of 2024 Financial Results Conference Call.

InfuSystem Holdings, Inc. (INFU) Q3 2024 Earnings Call Transcript

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports Third Quarter 2024 Financial Results.

InfuSystem Reports Third Quarter 2024 Financial Results

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Third Quarter 2024 Financial Results on November 7, 2024.

InfuSystem to Report Third Quarter 2024 Financial Results on November 7, 2024

Tactile Systems

The medical device market, a powerhouse sector, is projected to exceed $600 billion by 2025. This growth is fueled by a combination of factors, including an aging population, rising healthcare costs, and rapid technological advancements powered by advanced artificial intelligence (AI) and biotechnology.

The Future of Medical Devices: Two Strong Buys You Can't Miss

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate in Lytham Partners Fall 2024 Investor Conference on October 1, 2024.

InfuSystem to Participate in Lytham Partners Fall 2024 Investor Conference on October 1, 2024

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, and its joint venture partner Sanara MedTech Inc. (“Sanara”), announced today the execution of an exclusive United States distribution agreement with ChemoMouthpiece, LLC (“ChemoMouthpiece”).

InfuSystem and Sanara MedTech Inc. Announce Exclusive United States Distribution Agreement with ChemoMouthpiece, LLC

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate in Lake Street's 8th Annual Best Ideas Growth (BIG8) Conference September 12, 2024.

InfuSystem to Participate in Lake Street's 8th Annual Best Ideas Growth (BIG8) Conference September 12, 2024

InfuSystem's stock could soar in late 2024 and throughout 2025 after consolidating in the sub-$7.00/share range. INFU's underlying business is stronger than ever, with new partnerships and revenue streams set to surprise the market. The company's pivot toward partnering with established players is expected to drive revenue growth and expanding margins.

InfuSystem Set For Strong Second Half

InfuSystem Holdings, Inc. (NYSE:INFU ) Q2 2024 Earnings Call Transcript August 8, 2024 9:00 AM ET Company Participants Joe Dorame - Investor Relations Rich Dilorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Capital Group Jim Sidoti - Sidoti & Company Operator Good day, and welcome to the InfuSystem Holdings, Inc. Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.

InfuSystem Holdings, Inc. (INFU) Q2 2024 Earnings Call Transcript

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports Second Quarter 2024 Financial Results.

InfuSystem Reports Second Quarter 2024 Financial Results

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Distribution Agreement with Smith+Nephew for Negative Pressure Wound Therapy System and First Shipment of NPWT Systems.

InfuSystem Announces Distribution Agreement with Smith+Nephew for Negative Pressure Wound Therapy System and First Shipment of NPWT Systems

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Second Quarter 2024 Financial Results on August 8, 2024.

InfuSystem to Report Second Quarter 2024 Financial Results on August 8, 2024

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Present at Sidoti Small Cap Conference on June 12, 2024.

InfuSystem to Present at Sidoti Small Cap Conference on June 12, 2024

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces $20 Million Stock Repurchase Program.

InfuSystem Announces $20 Million Stock Repurchase Program

InfuSystem Holdings, Inc. (NYSE:INFU ) Q1 2024 Results Conference Call May 9, 2024 9:00 AM ET Company Participants Joe Dorame - Investor Relations Rich Dilorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Jim Sidoti - Sidoti & Company Aaron Warwick - Breakout Investors Operator Good morning, ladies and gentlemen, and welcome to the InfuSystem First Quarter 2024 Financial Results Conference Call. I will now turn the program over to Joe Dorame.

InfuSystem Holdings, Inc. (INFU) Q1 2024 Earnings Call Transcript

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports First Quarter 2024 Financial Results.

InfuSystem Reports First Quarter 2024 Financial Results

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report First Quarter 2024 Financial Results on May 9, 2024.

InfuSystem to Report First Quarter 2024 Financial Results on May 9, 2024

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K.

InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K

Airgain

AUO Corp

PAR Technology

Pinduoduo Inc - ADR

Frontier Group Holdings

VerifyMe, Inc.

Many high-flying growth stocks crashed back to earth when the 2021 boom cooled off. Companies that weren't consistently crushing earnings estimates got caught in the broader market downdraft.

Double Down: 7 Beaten-Down Growth Stocks to Buy Hand Over Fist

InfuSystem Holdings, Inc. (NYSE:INFU) Q4 2023 Earnings Conference Call March 14, 2022 9:00 AM ET

InfuSystem Holdings, Inc. (INFU) Q4 2023 Earnings Call Transcript

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2023.

InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2023

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Fourth Quarter and Full Year 2023 Financial Results on March 14, 2024.

InfuSystem to Report Fourth Quarter and Full Year 2023 Financial Results on March 14, 2024

InfuSystem stock has not performed well compared to the S&P 500, but the company has made significant investments that are expected to pay off in 2024 and beyond. The company's struggles over the past two years were due to making investments that will be monetized in 2024 and beyond. INFU's biomed and wound care businesses are expected to drive growth in 2024, with opportunities for expansion and increased profitability.

InfuSystem Holdings: 2024 Will Be A Year Of Monetization

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Present at Sidoti Small-Cap Virtual Conference on December 6, 2023.

InfuSystem to Present at Sidoti Small-Cap Virtual Conference on December 6, 2023

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate at 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023.

News for InfuSystem Hlds Stock (INFU)